Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2018The Journal of ImmunologyOpen Access

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

View Full Paper
Ask AI
Bookmark
Share

Authors

SSShivani SrivastavaYale UniversitySRStanley R. RiddellScripps Research Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Srivastava et al. (2018) studied this question.

synapsesocial.com/papers/69d9cfbd0f32475823a3c663https://doi.org/10.4049/jimmunol.1701155
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity2014 · 538 citations
  2. 2Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells2014 · 112 citations
  3. 3A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines2017 · 267 citations
  4. 4HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma2017 · 860 citations
  5. 5CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia2013 · 2,100 citations